In recent years, researchers have considered a potential link between beta-blockers and a decreased risk of cancer. This theory stems from the fact that beta-blockers inhibit the actions of the stress hormone norepinephrine. This, along with studies that found norepinephrine can promote the growth and spread of cancer cells, led researchers to reason that the beta-blockers could have anticancer properties.
However, a recent study published early online in Cancer revealed that the use of beta-blockers showed no reduction of colorectal cancer risk.
Lynch syndrome, also called hereditary nonpolyposis colorectal cancer (HNPCC), is the most common cause of hereditary endometrial cancer. It accounts for at least 2% to 3% of all endometrial cancer cases and 9% to 10% of endometrial cancer cases in women diagnosed younger than 50 years of age.1-3 Women with Lynch syndrome have a high lifetime risk for colorectal (30%- 52%)4 and endometrial (20%-71%)5 cancer. Read More ›
For patients with colorectal cancer (CRC), advances in molecular profiling have led to an explosion in novel agents specific for targets above and beyond the epidermal growth factor receptor (EGFR). Joseph Tabernero, MD, director of clinical research at Vall d’Hebron Institute of Oncology in Barcelona, Spain, previewed the future of treatment for CRC.
SAN DIEGO—Two studies presented at the 52nd annual meeting of the American Society for Radiation Oncology have found that the use of fast neutron radiotherapy (FNRT), a form of radiation that is about three times more powerful than typical photon radiotherapy, is highly effective and safe for patients with non–small-cell lung cancer (NSCLC).
Colorectal cancer (CRC) is the third most common cancer worldwide, and the fourth most common cause of death from cancer.1,2 It is estimated that in 2009, 146,970 men and women will have been diagnosed with cancer of the colon and rectum in the United States, and that 49,920 will have died from the disease.3 From 2002 to 2006 the median age of diagnosis was 71 years.3
To sign up for our newsletter or print publications, please enter your contact information below.